SiRNAs targeting eIF4E inhibit tumor growth and stimulate the cytotoxic effects of cisplatin in human breast cancer in vitro and in vivo, suggesting that cisplatin treatment in combination with eIF4E-siRNA therapy would be more successful [176]. The gene discussed is EIF4E; the disease is breast carcinoma.